
Novartis to acquire Regulus in $1.7B kidney drug deal
The basics: Novartis plans to acquire clinical stage biotech Regulus Therapeutics in a deal worth up to $1.7 billion. Under the terms announced April 30, the Swiss drugmaker will make an upfront payment of $800 million to the San Diego-based company. If …